anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Hepatic ischemia‒reperfusion injury (HIRI) is a common and inevitable complication of hepatic trauma, liver resection, or liver transplantation. It contributes to postoperative organ failure or tissue rejection, eventually affecting patient prognosis and overall survival. The pathological mechanism of HIRI is highly complex and has not yet been fully elucidated. The proposed underlying mechanisms include mitochondrial damage, oxidative stress imbalance, abnormal cell death, immune cell hyperactivation, intracellular inflammatory disorders and other complex events. In addition to serious clinical limitations, available antagonistic drugs and specific treatment regimens are still lacking. Therefore, there is an urgent need to not only clarify the exact etiology of HIRI but also reveal the possible reactions and bottlenecks of existing drugs, helping to reduce morbidity and shorten hospitalizations. We analyzed the possible underlying mechanism of HIRI, discussed various outcomes among different animal models and explored neglected potential therapeutic strategies for HIRI treatment. By thoroughly reviewing and analyzing the literature on HIRI, we gained a comprehensive understanding of the current research status in related fields and identified valuable references for future clinical and scientific investigations.
PROBLEM TO BE SOLVED: To obtain an inorganic ultraviolet-intercepting agent highly able to intercept ultraviolet rays and excellent in transparency by using titanium phosphate microparticles having a specified means particle diameter. SOLUTION: This agent comprises a titanium phosphate having a means particle diameter of 0.1μm or below, desirably a compound having a Ti/P atomic ratio of 0.5-1.5. Especially, titanium phosphate having a Ti/P atomic ratio of 0.8-1.0 possesses an excellent ability to intercept ultraviolet rays and excellent transparency and therefore is a desirable compound. When the titanium phosphate has a Ti/P atomic ratio smaller than 0.5 or larger than 1.5, there is the possibility of lowering the ability to intercept ultraviolet rays. Desirable examples of the titanium phosphates include Ti(OH)PO4 , TiPO4 and Ti(HPO4 )2 .  This agent is excellent in both the ability to intercept ultraviolet rays and transparency, so that it is used as, for example, a modifier for ultraviolet- intercepting coatings used for, e.g., windowpanes of a high-rise building or an automobile or also as a cosmetic additive because of its safety and good spread on the skin.
LPV/r: LPV/r monotherapy and anti HCV drugs for 12 months. All the patients will be followed-up for six months after the end of anti-HCV drugs for the evaluation of Sustained Virological Response (SVR). At the end of the co-treatment for HCV/HIV, each subject will be treated for HIV infection according to physician decisions.As anti-HCV drugs the patients will receive PEG-IFNa 2a 180 mcg/week + Ribavirin 1-1.2 g/day .At the end of the third month of combined therapy, only patients who reach an early virological response will continue anti-HCV drugs.
The participant's provider will receive an electronic alert in real time of the participant's positive screen for SU and a list of area substance treatment resources. The provider at their discretion will provide counseling or initiate a referral to in-clinic or community-based resources for SU assessment and treatment. Each of our clinical sites has case management resources for counseling and support for linkage to co-located SU treatment or community-based resources for inpatient or outpatient SU treatment as indicated at the discretion of the HIV/PrEP provider. SOC arm participants will not be assigned a coach. Study visit surveys and sample collection at baseline, 3, 6, 9, and 12 months are identical for intervention and SOC arm participants. Research personnel will make no attempts to provide brief intervention, motivational interviewing (MI), or case management.
Objective: The purpose of the current study was to investigate balance in children with attention deficit hyperactivity disorder contrasted to normal subjects. Furthermore, it studied the relationship between their balance and the total percentile scores of ADHD Rating Scale-IV.

Design: The study was a cross-sectional design. Methods: Sixty children were involved in this research from both sexes (42 boys and 18 girls) with age ranged from 60 to 84 months. They were subdivided into two groups based on the ADHD Rating Scale-IV. The control group included 30 normally developed children from both sexes (20 boys and 10 girls) with a mean age of 67.53 ± 1.41 months, and the total percentile scores of ADHD Rating Scale-IV ≤ 50. The study group comprised of 30 children from both sexes (22 boys and 8 girls) with attention deficit hyperactivity disorder (ADHD) with a mean age of 68.60 ± 4.62 months. The total percentile scores of ADHD Rating ScaleIV were ≥ 93. Both groups were investigated for their balance by Pediatric Balance Scale (PBS).
S0RL1 encodes the retromer-associated receptor SORL1 that functions in endosomal recycling. Rare variants in SORL1 have been associated with Alzheimer's disease (AD) and rare pathogenic variants are estimated to occur in up to 2.75% of early onset AD patients and in 1.5% of unrelated late onset AD patients. While truncation mutations are observed almost exclusively in AD patients, it is currently unknown which among the hundreds of rare missense variants identified in SORL1, are pathogenic. This question is addressed by relying on SORLl's distinct molecular architecture. First, a structure-guided sequence alignment was completed for all the protein domains. Next, proteins that contain domains homologous to those of SORL1 were identified, which include pathogenic variants for monogenic diseases. The analogous domain positions of these variants in the SORL1 protein sequence were identified and showed that variants in these positions similarly impair SORL1, and lead to AD. Together, the findings represent a comprehensive compendium on SORL1 protein variation and functional effects, which allowed for the prioritization of SORL1 genetic variants into high or moderate priority mutations. This compendium may be used by clinical geneticists for assessing variants they identify in patients, allowing further development of diagnostic procedures and patient counseling strategies. Ultimately, this compendium will inform investigations into the molecular mechanisms of endosomal recycling which will support the development of therapeutic treatment strategies for SORL1 variant-carrying patients.
Paroxetine (Deroxat®) Posology : 20 mg per day for 3 weeks. After 2 weeks of treatments, if indicated, physicians will prescribe until 50 mg.
The invention provides novel MTR-3 polypeptides, proteins, and nucleic acid molecules. In addition to isolated, full-length MTR-3 proteins, the invention further provides isolated MTR-3 fusion proteins, antigenic peptides and anti-MTR-3 antibodies. The invention also provides MTR-3 nucleic acid molecules, recombinant expression vectors containing a nucleic acid molecule of the invention, host cells into which the expression vectors have been introduced and non-human transgenic animals in which an MTR-3 gene has been introduced or disrupted. The present invention also provides methods and compositions for the diagnosis and treatment of cellular growth or proliferation disorders, e.g., cancer, including, but not limited to colon cancer. The invention further provides methods for identifying a compound capable of treating a cellular growth or proliferation disorder. The invention also provides methods for identifying a compound capable of modulating a cellular growth or proliferation disorder. In addition, the invention provides a method for treating a subject having a cellular growth or proliferation disorder characterized by aberrant MTR-3 polypeptide activity or aberrant MTR-3 nucleic acid expression.
A plurality of storage stable particles of uniform shape consists essentially of a plurality of allotropic organic compounds. Each of the allotropic organic compounds consists essentially of a uniform crystalline character and a plurality of crystalline domains. The organic compounds retain their crystalline character and the particles retaining their uniform shape on storage in aqueous media for at least about one month. A method for effecting solid state crystallization of an allotropic molecular organic compound in a particle of uniform size and shape comprises creating a formulation consisting essentially of an allotropic organic compound of mixed crystalline or both crystalline and amorphous form. The formulation is then fabricated into a plurality of particles of uniform shape. The particles are exposed to an atmosphere containing vapor of a solvent of the allotropic organic compound for a time sufficient to effect a solid state crystallization of the particles and then the particles are recovered. The allotropic organic compound in the recovered particles is a of a uniform crystalline structure, with the particles retaining their shape and can retain their shape on storage in aqueous media for at least one month. Preferably the allotropic organic compound is a sterol or steroid.
Compositions comprising an active oxygen-responsive antioxidant crystal, methods of making them, and methods for controlling the dissolution rate and/or altering the crystallization behavior of an antioxidant are disclosed. The crystals comprise an antioxidant and a disulfide- or diselenide-crosslinked polymer that is adsorbed onto a surface of the antioxidant. Upon exposure to an active-oxygen stimulus, the polymer de-crosslinks to release the antioxidant from the composition in an amount effective to counteract the stimulus. While prior approaches to altering dissolution rates have relied on passive zero- or first-order kinetics that are independent of ROS levels, the inventive compositions actively respond by releasing antioxidant in an amount proportional to the concentration of active-oxygen species present. The crystallization methods are simple and scalable. The antioxidant balances ROS concentration and allows formulators of nutritional supplements, drug therapies, and other applications to more effectively use antioxidants while avoiding undesirable levels of antioxidative stress.
JI-101 is a compound being developed for the treatment of patients with solid tumors; specifically patients for which no approved therapy or standard of care is available or have solid tumors and have failed standard of care therapy. JI-101 is an inhibitor of vascular endothelial growth factor receptor 2 (VEGFR2), platelet-derived growth factor receptor beta (PDGFRβ), and EphB4 receptor, each of which plays an important role in driving vascularization (angiogenesis and vasculogenesis) during normal development and tumorigenesis. JI-101 inhibits the growth of new blood vessels, which in turn, may slow or prevent the growth of tumors. The purpose of this open label study is to treat patients with advanced solid tumors, with increasing doses of JI-101, thereby providing information about the maximum tolerated dose (MTD). The study will also examine safety, tolerability, pharmacokinetics, pharmacodynamics, and may evaluate the effects of the drug on tumor metabolism. During this dose-escalation study, at least two patients will be dosed at each dose level (cohort). The patients must complete 21 days of dosing and safety results will be reviewed prior to any patients being assigned the next higher dose level. A continuous reassessment method will be utilized to escalate JI-101 doses between cohorts. Doses will be increased, with an anticipated high dose of 800mg per day. If the MTD is not reached, an optimal biologic dose (OBD) will be determined based on the highest doses that are tolerable with acceptable efficacy. The cohort at MTD or OBD will be expanded to include up to 30 patients with solid tumors to further explore the safety and tolerability of orally-administered JI-101.
The invention discloses a fleece-flower root-containing traditional Chinese medicine preparation and a preparation method thereof. The fleece-flower root-containing traditional Chinese medicine preparation comprises, by mass, 50-100 parts of fleece-flower root, 15-25 parts of cassia seed, 20-30 parts of poria cocos, 25-50 parts of Chinese angelica, 60-80 parts of eucommia, 50- 80 parts of rhizoma rehmanniae, 25-35 parts of ligusticum wallichii, 60-80 parts of mannitol and 1-2 parts of talcum powder. The fleece-flower root-containing traditional Chinese medicine preparation adopts fleece-flower root as a raw material, contains stibene glucoside as a main component, can be used for adjunctive treatment on dementia, apoplexy, coronary heart disease and angina pectoris, can be used for daily health care, can improve human immunity, can prevent eqpidemic diseases, can delay aging and can reduce fat. Through utilization of the natural plants, the fleece-flower root-containing traditional Chinese medicine preparation has no obvious toxic or side effect and high safety, can be absorbed easily, can produce effects fast, is convenient for use, can remove toxins, can eliminate carbuncle and can moisten the intestines to relax the bowels. The fleece-flower root-containing traditional Chinese medicine preparation can mainly treat scrofula and carbuncle, rubella pruritus and constipation due to intestinal dryness. Prepared fleece-flower root has effects of nourishing liver and kidney, boosting essence and blood, blacking beard and hair, strengthening muscles and bones, resisting oxidation, resisting aging, improving cognitive ability, improving immunity, reducing blood fat and resisting atherosclerosis. The preparation method has a low cost and simple processes and can be widely used.
Post-dural puncture headache leads to high morbidity and cost to the health system. Pregnant women have a higher incidence than other population groups. There are several treatments for post dural puncture headache mentioned in the literature, not all well established, with a wide heterogeneity of treatment between services. Sphenopalatine block then appears as an alternative treatment, having been described as effective in reports and case series, requiring comparative experimental studies.

OBJECTIVES: To evaluate the efficacy of sphenopalatine blockade in combination with multimodal treatment in reducing the incidence of epidural blood patch and pain intensity in patients who develop headache after dural puncture, compared with the clinical treatment in our service.

METHODS: A prospective randomized clinical, analytical study will be conducted at the Obstetric Center of the Central Institute of the University of São Paulo School of Medicine Hospital das Clínicas (ICHC-FMUSP). Women will be included who will undergo neuroaxis block for cesarean section, vaginal delivery or uterine curettage, and who later present headache after dural puncture, after evaluation and diagnosis by anesthesiologist. The patients will be divided into three groups at random. In group I, patients will receive clinical treatment according to the institution's old protocol for post dural puncture headache. In group II, patients will receive clinical treatment, according to the new protocol of the institution. In group III patients will receive clinical treatment, according to the new protocol of the institution, associated with sphenopalatine block. They will be reevaluated after 12, 24 and 48 hours, and a visual analog scale will be applied to evaluate improvement. The pain will be quantified before and after treatment. Pain intensity will be evaluated by verbal numerical scale (EVN), incidence of need for epidural blood buffer in each group, as well as length of hospital stay (in days).
This application proposes to evaluate the implementation of a theory-based HIV care enhancement and alcohol treatment intervention delivered by cell phone to patients in urban and rural areas. Engagement, retention, and adherence to care are necessary to achieve HIV suppression and antiretroviral therapy (ART) non-adherence can lead to treatment resistant genetic variants of HIV. People living with HIV often experience difficulty sustaining high-levels of treatment adherence and alcohol use is known to impede HIV care. Most factors that interfere with adherence to care are unanticipated and occur between clinical visits, including depression, ART side effects, and substance use. We will conduct a comparative effectiveness study to evaluate the implementation of a cell phone-delivered theory-based alcohol treatment and HIV care adherence counseling intervention. The intervention is grounded in the Behavioral Self-Regulation Model and utilizes brief cell phone counseling that includes monitoring adherence, provider support, and guided corrective feedback as well as interactive text message check-ins. This proactive approach with patients who drink is intended to increase engagement in care and facilitate reductions in drinking thereby improving retention to care and health outcomes. Brief counseling conducted via cell phones allows providers to detect and correct patient slippage from their care plan within a timeframe that can head-off missed appointments, ART non-adherence, and viral resistance. The intervention also includes interactive text (SMS) messaging that begins weekly and tappers off to further enhance engagement in care. Participants are 200 men and 200 women living in high-HIV prevalence remote communities who actively use alcohol and are receiving HIV treatment. Following screening, informed consent, and baseline assessments, participants will be allocated to either (a) the mobile alcohol behavioral self-regulation counseling enhancement to their usual care or (b) routine services provided in their usual care. Participants will be followed for 12-months post-intervention. The primary endpoints are retention to care, medication adherence assessed by unannounced pill counts and HIV RNA (viral load). The study will also evaluate the implementation processes including facilitators and barriers to engagement in care and a cost accounting of resources expended to achieve optimal outcomes. A team of internationally recognized experts in HIV treatment and behavioral research will form a working group to guide an in-depth implementation and cost evaluation. This study will inform the implementation of low-cost evidence-based care retention and adherence interventions in resource limited settings.
The green tea group will be instructed to drink 3 cups (230CC) of Chinese green tea (Wissotzky Tea Israel Ltd). Each tea bag contains 500 g of fine dried herb parts. Each cup contains 84 mg total catechin and 32 mg caffeine. The participants were instructed to leave the tea bag for 2 minutes before drinking.
Peritoneal fibrosis together with increased capillaries is the primary cause of peritoneal dialysis failure. Mesothelial cell loss is an initiating event for peritoneal fibrosis. We find that the elevated glucose concentrations in peritoneal dialysate drive mesothelial cell pyroptosis in a manner dependent on caspase-3 and Gasdermin E, driving downstream inflammatory responses, including the activation of macrophages. Moreover, pyroptosis is associated with elevated vascular endothelial growth factor A and C, two key factors in vascular angiogenesis and lymphatic vessel formation. GSDME deficiency mice are protected from high glucose induced peritoneal fibrosis and ultrafiltration failure. Application of melatonin abrogates mesothelial cell pyroptosis through a MT1R-mediated action, and successfully reduces peritoneal fibrosis and angiogenesis in an animal model while preserving dialysis efficacy. Mechanistically, melatonin treatment maintains mitochondrial integrity in mesothelial cells, meanwhile activating mTOR signaling through an increase in the glycolysis product dihydroxyacetone phosphate. These effects together with quenching free radicals by melatonin help mesothelial cells maintain a relatively stable internal environment in the face of high-glucose stress. Thus, Melatonin treatment holds some promise in preserving mesothelium integrity and in decreasing angiogenesis to protect peritoneum function in patients undergoing peritoneal dialysis.
Hepatocellular carcinoma (HCC) is the fastest-growing cause of cancer-related deaths worldwide. Chronic inflammation and fibrosis are the greatest risk factors for the development of HCC. Although the cell of origin for HCC is uncertain, many theories believe this cancer may arise from liver progenitor cells or stem cells. Here, we describe the activation of hepatic stem cells that overexpress the cholecystokinin-B receptor (CCK-BR) after liver injury with either a DDC diet (0.1% 3, 5-diethoxy-carbonyl 1,4-dihydrocollidine) or a NASH-inducing CDE diet (choline-deficient ethionine) in murine models. Pharmacologic blockade of the CCK-BR with a receptor antagonist proglumide or knockout of the CCK-BR in genetically engineered mice during the injury diet reduces the expression of hepatic stem cells and prevents the formation of three-dimensional tumorspheres in culture. RNA sequencing of livers from DDC-fed mice treated with proglumide or DDC-fed CCK-BR knockout mice showed downregulation of differentially expressed genes involved in cell proliferation and oncogenesis and upregulation of tumor suppressor genes compared with controls. Inhibition of the CCK-BR decreases hepatic transaminases, fibrosis, cytokine expression, and alters the hepatic immune cell signature rendering the liver microenvironment less oncogenic. Furthermore, proglumide hastened recovery after liver injury by reversing fibrosis and improving markers of synthetic function. Proglumide is an older drug that is orally bioavailable and being repurposed for liver conditions. These findings support a promising therapeutic intervention applicable to patients to prevent the development of HCC and decrease hepatic fibrosis.NEW & NOTEWORTHY This investigation identified a novel pathway involving the activation of hepatic stem cells and liver oncogenesis. Receptor blockade or genetic disruption of the cholecystokinin-B receptor (CCK-BR) signaling pathway decreased the activation and proliferation of hepatic stem cells after liver injury without eliminating the regenerative capacity of healthy hepatocytes.
BACKGROUND: Obesity is a global health problem, and its connection with social and environmental factors is well-established. Social factors, such as urban segregation, may impact obesity through various mechanisms, including food and physical activity environments, as well as social norms and networks. This multilevel study aims to examine the effect of socio-economic residential segregation of Latin American cities on the obesity of individuals within those cities.
METHODS: We analyzed data from national surveys for a total of 59,340 individuals of 18-70 years of age, conducted in 156 cities across Brazil, Chile, Colombia, and Mexico between 2007 and 2013. We adjusted two-level linear mixed models for body mass index (BMI) stratified by sex and country, controlling for age, educational level and poverty. Separate models were built for dissimilarity and isolation segregation indices.
RESULTS: The relationships between segregation indices and BMI were mostly not statistically significant, and in some cases, they were opposite to what was expected. The only significant relationships were observed in Colombian men, using the dissimilarity index (-7.5 [95% CI: -14.4, -0.5]) and in Colombian women, using the isolation index (-7.9 [95% CI: -14.1, -1.7]).
CONCLUSIONS: While individual-level factors cannot fully explain differences among people in the same city, segregation indices may help. However, we found that in some cases, the relationship between BMI and segregation indices is opposite to what is expected based on prior literature. This should be considered in examining the phenomenon. Further research on obesogenic environments in segregated neighborhoods could provide valuable evidence.